Covidien raises 2013 outlook as Q1 exceeds expectations
January 25, 2013 by MassDevice staff
Medical device company Covidien increases its guidance for 2013 on above-market growth in its medical device sales and a rosy outlook on emerging markets.
Medtech titan Covidien (NYSE:COV) gained some points on Wall Street after raising its 2013 sales outlook on the strength of its 1st quarter results and an optimistic outlook on the company's emerging market potential.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
- How to simplify consents
Navigation
NEWS
J&J's Synthes unit wins $16M ruling in patent fight with Globus Medical
A Delaware jury sides with Johnson & Johnson's DePuy-Synthes subsidiary in a patent spat over 3...
Aneurysm: Covidien touts pivotal study on Pipeline embolization device
Results of pivotal study on Covidien subsidiary eV3's Pipeline cerebral aneurysm device, published in...
ForSight Vision5 gets new CEO, closes $9.3M funding round
Delphi Ventures' John Maroney joins ForSight Vision5 as president, CEO & Director as the...
Diabetes: Echo Therapeutics sends pre-submission package to FDA for Symphony needle-free CGM
Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-...
Real-world results cast doubt on renal denervation for high blood pressure
Study results revealed in Europe this week cast doubt on the efficacy of renal denervation for...
